SciELO - Scientific Electronic Library Online

 
vol.61 número3Etiología neurógena en pacientes con disfunción erectilCarcinoma de los ductos de Bellini: aportación de dos nuevos casos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Archivos Españoles de Urología (Ed. impresa)

versión impresa ISSN 0004-0614

Resumen

CANDEBAT MONTERO, L. H. et al. Peyronie's disease: treatment with interferon and laser. Arch. Esp. Urol. [online]. 2008, vol.61, n.3, pp.413-423. ISSN 0004-0614.

Objectives: To evaluate comparatively the results of treatment with interferon, laser and their association in a group of patients with Peyronie’s disease. Methods: We performed an experimental study to evaluate the main results of the treatment of Peyronie’s disease with interferon and laser, at Hospital Provincial Universitario "Saturnino Lora Torres" and Hospital General Universitario "Dr. Juan Bruno Zayas Alfonso" in the city of Santiago de Cuba from January 2003 to July 2005. Ninety-six patients were included, divided into three treatment groups: interferon, laser and interferon plus laser. After initial evaluation, treatment was started and continued for 28 weeks, with reevaluation six and 12 months after the end of treatment. Results: Final results with combined interferon and laser were: symptoms improvement 84.7%, decrease of the size of the fibrous plaque 90.6% and decrease of penile curvature 87.5%. Conclusions: The combination of both therapies resulted to be more effective than each of them separately, so the recommendation is to incorporate it as another therapeutic alternative in Peyronie’s disease.

Palabras clave : Peyronie’s disease; Interferon; Laser.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons